Menu Back to Continuing-Education

Continuing Education

DIA 2022 brings together key thought leaders and innovators from industry, academia, regulatory and government agencies, health, patient, and philanthropic organizations from around the globe and across all disciplines involved in the discovery, development, and lifecycle management of healthcare products. DIA 2022 is intended to strengthen professionals’ understanding of cross-cutting concepts in biopharmaceutical development and foster collaboration across disciplines for better health outcomes.

View DIA 2022 UAN and PMI Numbers

Learning Objectives

At the conclusion of the DIA 2022 Global Annual Meeting, participants should be able to:

  • Examine the roles and relationships of data science, data analytics, and biostatistics in the innovative application of data from all sources to bring effective therapies to patients
  • Discuss the changing data landscape with a focus on use of real-world data/real-world (RWD/RWE) evidence for use in regulatory assessments
  • Discuss the development and application of data standards, and approaches and methodologies for ensuring data quality, applicability, interoperability, and appropriate use throughout the medical product lifecycle
  • Examine how to develop cross functional collaborations within companies and engage with regulators to achieve diversity goals, and identify concrete strategies to achieve these goals through community partnerships, training, and other proactive initiatives
  • Describe the current and future uses of innovative technology in the generation and collection of patient data in support of clinical research and post-market assessment to improve patient outcomes
  • Discuss the current statistical thinking that informs policy, regulation, development, review, and lifecycle management of medical products
  • Discuss the application of new statistical methodologies to address complex problems in the design and conduct of research studies to streamline the development of innovative medical products, and reduce bias in the healthcare system
  • Identify common ethical issues currently facing researchers, how different stakeholder communities may differ in their stances on these issues; and evaluate proposed responses on the part of sponsors
  • Explain key challenges and opportunities drug development for rare diseases including trial design, use of real-world data, risk evaluation and management, current regulatory pathways and frameworks, innovative technology, and how to expedite patient access
  • Describe principles of benefit-risk assessment and management in the development, review and approval, and post-market phases of new medical products and therapies, including advanced therapies and the utility of including the patient voice
  • Summarize issues in clinical and post-market safety data identification and selection, collection, analysis, and reporting
  • Discuss the continued impact of the COVID-19 pandemic on regulatory review and compliance, regulatory reliance, data collection and analysis, clinical trial design and conduct, medicines availability, and the discussion on healthcare reform
  • Discuss approaches and methodologies for incorporating patient perspective in the discovery, development, regulatory review, and lifecycle management of medical products to ensure that their development meets the needs and provides quality outcomes for patient health
  • Describe meaningful engagement of patients with sponsors, regulators, and other stakeholders throughout the medical product lifecycle
  • Describe current issues and approaches in designing and implementing clinical trials, including patient recruitment and integration, site selection, and management of multi-regional clinical trials
  • Compare the current regional regulatory and public policy environment pertaining to pharmaceuticals and related products
  • Discuss the regulatory and economic factors that impact the global biopharmaceutical industry
  • Evaluate the current landscape for global regulatory convergence and discuss the outcomes of harmonization efforts lead by ICH, ICMRA, WHO, and others who are leading these endeavors
  • Evaluate how regulatory intelligence can be applied in global biopharmaceutical product development strategies throughout the development cycle
  • Examine the challenges and opportunities in assessing medical product value and enhancing access including the roles of technological innovation and analytics, policy, and stakeholder collaboration in improving access to needed and affordable therapies
  • Interpret and apply quality standards, regulations, and guidelines for medical product development and lifecycle management to ensure that products are safe, efficacious, and available to patients who need them most
  • Discuss regulations and risk-based approaches for ensuring the integrity and quality of CMC submissions, manufacturing processes and data, and quality systems in the current regulatory and technological environments, both regionally and globally
  • Identify best practices to foster professional development, improve workplace dynamics, increase productivity, enhance interpersonal relationships, value diversity, and keep abreast of current hiring practices, leadership opportunities, and new technology trends
  • Describe approaches to inspections that drive regulatory compliance, identify process efficiency, and reduce gaps
  • Create effective project management strategies to maximize productivity in a drug development partnership, minimize risk, and utilize analytics and artificial intelligence to enhance decision-making

Specific learning objectives for each offering can be found on the DIA 2022 website under the program in the coming months.

Select short courses and program offerings (including sessions, forums, and workshops) may be approved for AMA PRA Category 1 Credits™, pharmacy or nursing contact hours, Project Management Institute (PMI) professional development units (PDUs), or International Association for Continuing Education and Training (IACET) continuing education units (CEUs). Continuing education credit information will be clearly identified on the DIA 2022 website with the statement CME, Pharmacy, Nursing, or PMI PDUs. CE credits are not available for the Innovation Theater presentations, Content Hubs, Community Rounds, Sponsored events, Solution Circles, Spotlight Symposia, Lunch and Learns, and On-Demand content.

View instructions for requesting CE credits

  • Joint Accreditation Statement

    Joint Accreditation Statement logoIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DIA. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this live activity for a maximum of 13 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 13 contact hours. California Board of Registered Nursing, Provider Number 13485, approved for 13 contact hours.

  • Accreditation Council for Pharmacy Education (ACPE)

    ACPE logoDIA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is designated for up to 13 contact hours or 1.3 continuing education units (CEU’s).
    ACPE Credit Requests MUST BE SUBMITTED by Friday, August 5, 2022. DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. All ACPE-certified activity credit requests need to be submitted through DIA’s My Transcript within 45-days post activity. If ACPE credit is not requested by Friday August 5, 2022, the CEU request will not be transmitted through to the CPE Monitor. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit.

  • American Nurses Credentialing Center (ANCC)

  • ACPE logo

    PIM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    PMIDIA has been reviewed and approved as a provider of project management training by the Project Management Institute (PMI).
    Participants may receive up to 6 professional development units (PDUs) for attending the Annual Meeting program offerings. All approved DIA designated PMI numbers for approved offerings are found on the DIA 2022 Global Annual Meeting website on each designated offering description.

    The PMI Registered Education Provider logo is a registered mark of the Project Management Institute, Inc.

  • International Association for Continuing Education and Training (IACET)

    IACETDrug Information Association (DIA) is accredited by the International Association for Continuing Education and Training (IACET) and is authorized to issue the IACET CEU. As an IACET Accredited Provider, DIA offers CEUs for its programs that qualify under the ANSI/IACET Standard. DIA is authorized by IACET to offer a maximum of 2.4 CEUs for this program.

    IACET credit available for Short Courses only.

  • Continuing Legal Education

    For attorneys who would like to receive continuing legal education credits for attending DIA 2022, please complete your state’s application for credit and submit accordingly. If you require additional information, please contact

  • Statements of Credit

    Participants who would like to receive continuing education credit for DIA 2022 must scan their DIA name badge at each offering to record their attendance. Participants must scan their badges within 15 minutes of the start of the offering. Participants who do not scan their badges within the allotted time will not be eligible to request the available continuing education credits for that offering. If a participant attends multiple offerings within the same timeframe, only the last scanned entry will be recorded. Please be sure to complete your session evaluation at the end of each day, located at: Further instructions for requesting your statement of credit will be provided in the final program.

  • Disclaimer

    Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the DIA. Speakers, agenda, and CE information are subject to change without notice.

    Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

  • Disclosure of Conflicts of Interest

    The Postgraduate Institute for Medicine (PIM) and DIA require instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM and DIA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Disclosure statements will be available under the Continuing Education Tab on the DIA 2022 website.

  • Americans with Disabilities Act (ADA)

    Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Read ACCME Standards for Commercial Support.
Read DIA’s Grievance Policy.
Read DIA's Privacy Policy.

Registration Rates

Back to DIA 2022

Back to